Sygnature Discovery has begun expanding into new laboratories at Bruntwood SciTech’s Alderley Park, Cheshire, adding Chemistry and Biology expertise to its DMPK and Translational Oncology teams already present on the site.
This expansion turns Alderley Park into a second co-located, integrated site for Sygnature.
“This is a tremendous opportunity for Sygnature. Increasing demand for our services has driven our decision to expand, and Alderley Park, with its well-earned reputation here and internationally, provides the ideal home for our new integrated site,” Dr Simon Hirst, CEO & Founder, Sygnature Discovery, said. “With exceptional facilities tailored to our needs, an incredible set of neighbors operating on-site, and a phenomenal talent pool for us to draw from, we are set for a bright future at Alderley Park.”
The “Cheshire Science Corridor” provides a experienced talent pool from which Sygnature can recruit for its new laboratories.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!
“UK life sciences has a once-in-a-generation opportunity to establish itself as a world leader, and businesses like Sygnature Discovery will be at the forefront of that push,” Dr Kath Mackay, Managing Director, Bruntwood SciTech - Alderley Park, said. “Sygnature’s expansion will enable it to better collaborate within the ecosystem of companies already based here, in turn driving innovation, and make it more attractive to the talent on offer on its doorstep. We’re proud to be playing our part in helping Sygnature deliver vital drug discovery research that will have long-lasting benefits for patients.”